JAKAFI/JAKAVI (ruxolitinib)
Revenue Exposure
Incyte depends heavily on ruxolitinib revenues; decline would materially harm the business.
Relevance 95·Dependency 90·Confidence 98
Source evidence
“We depend heavily on JAKAFI/JAKAVI (ruxolitinib), and if we are not able to maintain revenues from JAKAFI/JAKAVI or those revenues decrease, our business may be materially harmed.”
JAKAFI (ruxolitinib)
Revenue Exposure
Incyte's revenues depend substantially on JAKAFI; loss of exclusivity in 2028 and competing product launches are direct revenue risks.
Relevance 95·Dependency 90·Confidence 98
Source evidence
“we depend substantially on product revenues from JAKAFI. We must develop and commercialize new products to achieve revenue growth and to offset revenue losses from the loss of product exclusivity of JAKAFI in 2028”
patent exclusivity portfolio
Legal Exposure
Core products lose basic exclusivity starting 2028 (JAKAFI/OPZELURA/ruxolitinib), exposing revenues to generic competition.
Relevance 90·Dependency 85·Confidence 90
Source evidence
“JAKAFI/JAKAVI (ruxolitinib) Estimated Minimum Market Exclusivity Dates 2028 2028 2028”
JAKAFI supply depends on three qualified API manufacturers and two drug product manufacturers, with ruxolitinib raw materials sourced from China.
Relevance 90·Dependency 75·Confidence 85
Source evidence
“For JAKAFI and ICLUSIG, we have two qualified third-party manufacturers from which we can source commercial drug product.”
third-party manufacturers
Supplier Dependency
Reliance on third-party manufacturers creates risk of drug supply constraints, trial delays, increased costs, and regulatory approval withdrawal.
Relevance 85·Dependency 85·Confidence 95
Source evidence
“Our reliance on others to manufacture our drug products and drug candidates could result in drug supply constraints, delays in clinical trials, increased costs, and withdrawal or denial of regulatory approvals.”
specialty pharmacies and wholesalers
Customer Exposure
Loss of or reduced sales to any one specialty pharmacy or wholesaler could harm operations and financial condition.
Relevance 85·Dependency 80·Confidence 95
Source evidence
“the loss of, or significant reduction in sales to, any one of these specialty pharmacies or wholesalers could harm our operations and financial condition”
US drug pricing / Medicare & Medicaid reimbursement proposals
Regulatory Exposure
Healthcare reform and Medicare/Medicaid drug pricing changes could reduce pricing and profitability of pharmaceuticals.
Relevance 85·Dependency 70·Confidence 90
Source evidence
“Healthcare reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators' products and drug candidates.”
Inflation Reduction Act of 2022 (Part D Discount Program)
Regulatory Exposure
IRA Part D changes require 10%/20% discounts from 2025, but Incyte's small biotech exemptions (negotiation exemption through 2028, phased-in discounts) reduced its 2025 Part D sales allowances.
Relevance 85·Dependency 70·Confidence 95
Source evidence
“In 2025, we saw a reduction in our sales allowances owed under Medicare Part D, due to changes to the Part D Discount Program”
Ruxolitinib phosphate raw materials (API for JAKAFI and OPZELURA) are supplied by Chinese-based companies, creating dependency on Chinese supply chains.
Relevance 85·Dependency 70·Confidence 90
Source evidence
“currently raw materials used to manufacture ruxolitinib phosphate, the API in JAKAFI and OPZELURA, are supplied by Chinese-based companies.”
Wilmington, Delaware
Revenue Exposure
Most drug discovery, research, development and marketing activities are concentrated at the Wilmington headquarters; loss of access would interrupt the business.
Relevance 80·Dependency 75·Confidence 90
Source evidence
“Our facility in Wilmington, Delaware is our headquarters and is also where we conduct most of our drug discovery, research, development and marketing activities.”
Supply chain disruption
Supplier Dependency
Single-source and limited-source supplier model means a supplier failure could interrupt clinical trials and commercial supply; long lead times reduce flexibility.
Relevance 80·Dependency 70·Confidence 90
Source evidence
“we may have less flexibility to adjust our supply in response to changes in demand than if we had shorter lead times.”
fully integrated pharmaceutical companies
Competitive Exposure
Competitors with substantially greater resources may commercialize competing products or achieve superior patent/regulatory positions.
Relevance 80·Dependency 65·Confidence 90
Source evidence
“Many companies and institutions... have substantially greater financial resources, larger drug discovery, development and commercial staffs and significantly greater experience”
Government and private payor drug pricing initiatives
Cost Driver
Government and private payor pricing initiatives are an explicit challenge to Incyte's future product revenues.
Relevance 80·Dependency 60·Confidence 93
Source evidence
“Our product revenues also face challenges from economic conditions and drug pricing initiatives driven by governments and private payors.”
in-licensing partners (ARIAD/Takeda, MacroGenics, Merus, Xencor, Syndax, Enable Injections)
Technology Dependency
Key products (retifanlimab from MacroGenics, tafasitamab from Xencor, axatilimab from Syndax) depend on licenses with milestone and royalty obligations.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“Retifanlimab licensed from MacroGenics, Inc.”
FDA and healthcare fraud/abuse regulation
Regulatory Exposure
FDA and foreign agencies regulate critical activities including clinical studies, manufacturing, promotion and distribution; violations could bring fines, penalties and exclusion from Medicare/Medicaid; company previously faced an inquiry into speaker and patient assistance programs.
Relevance 75·Dependency 65·Confidence 85
Source evidence
“Violations of governmental regulation by us, our vendors or donation recipients may be punishable by criminal and civil sanctions, including damages, fines and penalties and exclusion from participation in government programs, including Medicare and Medicaid.”
US-China tensions
Geopolitical Exposure
A China-US trade dispute or Chinese government export actions would block supply of ruxolitinib raw materials, affecting manufacturing and operating results.
Relevance 75·Dependency 55·Confidence 90
Source evidence
“an international trade dispute between China and the United States or any other actions by the Chinese government that would limit or prevent Chinese companies from supplying these materials would adversely affect our ability to manufacture and supply our products to meet market needs”
PBMs, pharmacies and wholesalers
Customer Exposure
Cyber disruption of PBM/pharmacy/wholesaler systems could block claims processing and prescription fulfillment, reducing net product revenues.
Relevance 70·Dependency 65·Confidence 90
Source evidence
“the ability to process claims and fulfill prescriptions could be impacted, which could result in adverse effects on our net product revenues.”
General Data Protection Regulation
Regulatory Exposure
GDPR imposes fines up to €20 million or 4% of annual global revenue for noncompliance with data privacy obligations in the EU.
Relevance 70·Dependency 60·Confidence 95
Source evidence
“in the EU under the General Data Protection Regulation, potential fines for noncompliance are up to €20 million or 4% of annual global revenue, whichever is greater.”
Yverdon, Switzerland
Manufacturing Dependency
Internal biologic drug substance production is concentrated at the Yverdon facility, which manufactures MONJUVI/MINJUVI drug substance.
Relevance 65·Dependency 55·Confidence 90
Source evidence
“The Yverdon facility started to manufacture MONJUVI/MINJUVI drug substance during the fourth quarter of 2022.”
America Invents Act
Legal Exposure
AIA review proceedings increase uncertainty over U.S. patent validity, which could shorten protection and allow generic competition.
Relevance 65·Dependency 55·Confidence 95
Source evidence
“third parties are now able to challenge the validity of issued U.S. patents through various review proceedings; thus rendering the validity of U.S. patents more uncertain.”
CROs and contract manufacturers
Supplier Dependency
Incyte relies on third-party hosted IT systems and vendors including CROs and contract manufacturers; disruption of their business continuity plans could interrupt operations.
Relevance 60·Dependency 55·Confidence 85
Source evidence
“If our business continuity and disaster recovery plans and procedures or those of our vendors, including our CROs and contract manufacturers, were disrupted, inadequate or unsuccessful in the event of a problem, we could experience an interruption of all or a portion of our operations”
geopolitical events and trade conflicts
Geopolitical Exposure
Russian invasion of Ukraine, Middle East conflicts, and tariffs/trade conflicts are cited as risks to the business and clinical trial conduct.
Relevance 55·Dependency 45·Confidence 85
Source evidence
“the impact of tariffs and trade conflicts and the effects of any economic slowdown”
artificial intelligence
Technology Dependency
AI is increasingly used in the biopharmaceutical industry and by attackers; inaccurate AI analyses could cause competitive harm, legal liability, and IP leakage.
Relevance 55·Dependency 40·Confidence 90
Source evidence
“the use of artificial intelligence is increasing in the biopharmaceutical industry. As with many developing technologies, artificial intelligence presents risks and challenges that could affect its further development, adoption, and use, which could affect our business.”